Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Eriksson, BI; Borris, LC; Dahl, OE; Haas, S; Huisman, MV; Kakkar, AK; Muehlhofer, E; Dierig, C; Misselwitz, F; Kälebo, P; ODIXa-HIP Study Investigators 
Titel:
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. 
Abstract:
BACKGROUND: Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders. METHODS AND RESULTS: This randomized, double-blind, double-dummy, active-comparator-controlled, multinational, dose-ranging study assessed the efficacy and safety of once-daily rivaroxaban relative to enoxaparin for prevention of venous thromboembolism in patients undergoing elective total hip replacement. Patie...    »
 
Zeitschriftentitel:
Circulation 
Jahr:
2006 
Band / Volume:
114 
Heft / Issue:
22 
Seitenangaben Beitrag:
2374-81 
Sprache:
eng 
Print-ISSN:
0009-7322 
TUM Einrichtung:
r experimentelle Onkologie und Therapieforschung